Dishman Pharmaceuticals & Chemicals Ltd has successfully completed US FDA inspection for its facility located at, Bavla, which is a 100% EOU, to manufacture Eprosartan Mesylate, an anti hyper-tension drug, to be supplied to Solvay Pharmaceuticals, BV. The company is one of the two companies in the world with whom Solvay has entered into a long-term agreement for supply of newly developed molecule, whose patent is to expire in 2013, claimed the release.

With this event, Solvay will source its requirements for US markets from the company. Solvay has increased the quantity of Eprosartan Mesylate to be supplied by the company 50%.

Eprosartan Mesylate is produced from three starting materials, whose process technology was developed by the Company at it R&D, and Solvay having recognized the efforts put in by the Company in this development has entered into long-term Agreement to procure these Starting Materials to manufacture Eprosartan Mesylate by the second supplier from whom Solvay is outsourcing its balance requirement of Eprosartan Mesylate.